dalteparin has been researched along with Graft Occlusion, Vascular in 13 studies
Dalteparin: A low-molecular-weight fragment of heparin, prepared by nitrous acid depolymerization of porcine mucosal heparin. The mean molecular weight is 4000-6000 daltons. It is used therapeutically as an antithrombotic agent. (From Merck Index, 11th ed)
Graft Occlusion, Vascular: Obstruction of flow in biological or prosthetic vascular grafts.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Using a computer algorithm 284 patients with lower limb ischemia, most with pre-operative ischemic ulceration or partial gangrene, from 12 hospitals were randomised, after PABG, to 5000 IU dalteparin or placebo injections once daily for 3 months." | 9.11 | Effects of three months of low molecular weight heparin (dalteparin) treatment after bypass surgery for lower limb ischemia--a randomised placebo-controlled double blind multicentre trial. ( Drott, C; Gelin, J; Groth, O; Hensäter, M; Jensen, N; Jivegård, L; Johansson, G; Konrad, P; Lindberg, B; Lindhagen, A; Lundqvist, B; Oden, A; Ortenwall, P; Smith, L; Stenberg, B; Thornell, E; Wingren, U, 2005) |
| "Using a computer algorithm 284 patients with lower limb ischemia, most with pre-operative ischemic ulceration or partial gangrene, from 12 hospitals were randomised, after PABG, to 5000 IU dalteparin or placebo injections once daily for 3 months." | 5.11 | Effects of three months of low molecular weight heparin (dalteparin) treatment after bypass surgery for lower limb ischemia--a randomised placebo-controlled double blind multicentre trial. ( Drott, C; Gelin, J; Groth, O; Hensäter, M; Jensen, N; Jivegård, L; Johansson, G; Konrad, P; Lindberg, B; Lindhagen, A; Lundqvist, B; Oden, A; Ortenwall, P; Smith, L; Stenberg, B; Thornell, E; Wingren, U, 2005) |
| " The general use and correct dosage of low-molecular-weight heparin, however, are still under debate." | 2.70 | Low-molecular-weight heparin in arterial reconstructive surgery: a double-blind, randomized dose-finding trial. ( Eckmann, C; Kujath, P; Misselwitz, F, 2002) |
| " We aimed to determine whether current enoxaparin dosing regimens effectively achieve anti-factor Xa concentrations within prophylactic goal ranges in this patient population." | 1.48 | Establishment of prophylactic enoxaparin dosing recommendations to achieve targeted anti-factor Xa concentrations in children with CHD. ( Israel, EN; Mastropietro, CW; Thomas, CA, 2018) |
| "6 IU÷ml was applied, the present dosing method led to over-anticoagulation in more than half of the patients." | 1.42 | Anticoagulation with dalteparin and nadroparin in nocturnal haemodialysis. ( van Jaarsveld, BC; Verhave, G; Weijmer, MC, 2015) |
| "The relative number of grafts with thrombus free surface was increased in the unrestricted blood flow situation." | 1.29 | Effect of dextran and enoxaparin on early ePTFE graft thrombogenicity in sheep. ( Bergqvist, D; Lindblad, B; Lundell, A; Matthiasson, SE, 1995) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (15.38) | 18.2507 |
| 2000's | 7 (53.85) | 29.6817 |
| 2010's | 4 (30.77) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Verhave, G | 1 |
| Weijmer, MC | 1 |
| van Jaarsveld, BC | 1 |
| Israel, EN | 1 |
| Thomas, CA | 1 |
| Mastropietro, CW | 1 |
| Romero-Castro, MJ | 1 |
| Seoane-García, T | 1 |
| Chaparro-Muñoz, M | 1 |
| García-Borbolla, R | 1 |
| García-Rubira, JC | 1 |
| Barbarash, LS | 1 |
| Burkov, NN | 1 |
| Kudriavtseva, IuA | 1 |
| Anufriev, AI | 1 |
| Zhuravleva, IIu | 1 |
| Matthiasson, SE | 1 |
| Bergqvist, D | 2 |
| Lundell, A | 1 |
| Lindblad, B | 1 |
| Logason, K | 2 |
| Tramuta, DA | 1 |
| Kereiakes, DJ | 1 |
| Dippel, EJ | 1 |
| Lengerich, R | 1 |
| Broderick, TM | 1 |
| Abbottsmith, CW | 1 |
| Whang, DD | 1 |
| Roth, EM | 1 |
| Schneider, JF | 1 |
| Howard, W | 1 |
| Shimshak, TM | 1 |
| Wang, JC | 1 |
| Goldhaber, SZ | 1 |
| Popma, JJ | 1 |
| Kiesz, RS | 1 |
| Buszman, P | 1 |
| Martin, JL | 1 |
| Deutsch, E | 1 |
| Rozek, MM | 1 |
| Gaszewska, E | 1 |
| Rewicki, M | 1 |
| Seweryniak, P | 1 |
| Kosmider, M | 1 |
| Tendera, M | 1 |
| Gramse, CA | 1 |
| Hingorani, A | 1 |
| Ascher, E | 1 |
| Kujath, P | 1 |
| Eckmann, C | 1 |
| Misselwitz, F | 1 |
| Jivegård, L | 1 |
| Drott, C | 1 |
| Gelin, J | 1 |
| Groth, O | 1 |
| Hensäter, M | 1 |
| Jensen, N | 1 |
| Johansson, G | 1 |
| Konrad, P | 1 |
| Lindberg, B | 1 |
| Lindhagen, A | 1 |
| Lundqvist, B | 1 |
| Oden, A | 1 |
| Smith, L | 1 |
| Stenberg, B | 1 |
| Thornell, E | 1 |
| Wingren, U | 1 |
| Ortenwall, P | 1 |
5 trials available for dalteparin and Graft Occlusion, Vascular
| Article | Year |
|---|---|
Low-molecular weight heparin versus dextran in the prevention of early occlusion following arterial bypass surgery distal to the groin.
Topics: Aged; Anticoagulants; Dextrans; Enoxaparin; Graft Occlusion, Vascular; Humans; Time Factors; Vascula | 1998 |
Local delivery of enoxaparin to decrease restenosis after stenting: results of initial multicenter trial: Polish-American Local Lovenox NIR Assessment study (The POLONIA study).
Topics: Anticoagulants; Aspirin; Drug Administration Routes; Drug Delivery Systems; Enoxaparin; Female; Foll | 2001 |
Low molecular weight heparin (enoxaparin) versus dextran in the prevention of early occlusion following arterial bypass surgery distal to the groin.
Topics: Anticoagulants; Chi-Square Distribution; Dextrans; Enoxaparin; Female; Graft Occlusion, Vascular; Hu | 2001 |
Low-molecular-weight heparin in arterial reconstructive surgery: a double-blind, randomized dose-finding trial.
Topics: Aged; Anticoagulants; Arterial Occlusive Diseases; Blood Vessel Prosthesis Implantation; Dose-Respon | 2002 |
Effects of three months of low molecular weight heparin (dalteparin) treatment after bypass surgery for lower limb ischemia--a randomised placebo-controlled double blind multicentre trial.
Topics: Aged; Dalteparin; Double-Blind Method; Drug Administration Schedule; Female; Fibrinolytic Agents; Fo | 2005 |
8 other studies available for dalteparin and Graft Occlusion, Vascular
| Article | Year |
|---|---|
Anticoagulation with dalteparin and nadroparin in nocturnal haemodialysis.
Topics: Anticoagulants; Blood Coagulation; Dalteparin; Dose-Response Relationship, Drug; Female; Follow-Up S | 2015 |
Establishment of prophylactic enoxaparin dosing recommendations to achieve targeted anti-factor Xa concentrations in children with CHD.
Topics: Anticoagulants; Central Venous Catheters; Dose-Response Relationship, Drug; Enoxaparin; Factor Xa; F | 2018 |
A 70-Year-Old Woman With a Prosthetic Mitral Valve and Sudden Chest Pain.
Topics: Aged; Angina Pectoris; Coronary Thrombosis; Enoxaparin; Female; Fibrinolytic Agents; Graft Occlusion | 2018 |
[Comparative analysis of arterial bioprostheses with various antithrombotic modification].
Topics: Biological Availability; Bioprosthesis; Blood Vessel Prosthesis; Blood Vessel Prosthesis Implantatio | 2012 |
Effect of dextran and enoxaparin on early ePTFE graft thrombogenicity in sheep.
Topics: Animals; Blood Vessel Prosthesis; Carotid Artery, Common; Dextrans; Double-Blind Method; Drug Therap | 1995 |
Combination enoxaparin-abciximab therapy during coronary intervention: the next standard of care?
Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Combined Modality Therapy; | 2000 |
Use of enoxaparin in a patient with unstable angina.
Topics: Angina, Unstable; Blood Chemical Analysis; Cardiac Catheterization; Coronary Angiography; Coronary A | 2000 |
Postoperative anticoagulation in vascular surgery: part 1. A retrospective comparison of clinical outcomes for unfractionated heparin versus low-molecular-weight heparin.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Blood Transfusion; Drug Monitoring; Enoxaparin; Fema | 2001 |